
Christina Bradley
Examiner (ID: 14474, Phone: (571)272-9044 , Office: P/1675 )
| Most Active Art Unit | 1654 |
| Art Unit(s) | 1654, 1675 |
| Total Applications | 1470 |
| Issued Applications | 829 |
| Pending Applications | 173 |
| Abandoned Applications | 517 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20480363
[patent_doc_number] => 12528834
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-20
[patent_title] => Method for producing peptide compound
[patent_app_type] => utility
[patent_app_number] => 17/763185
[patent_app_country] => US
[patent_app_date] => 2020-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7129
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763185
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/763185 | Method for producing peptide compound | Sep 13, 2020 | Issued |
Array
(
[id] => 18019049
[patent_doc_number] => 20220370548
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => NEUROLOGICAL DISEASE TREATMENT WITH COMPLEMENT INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/642096
[patent_app_country] => US
[patent_app_date] => 2020-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26629
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -106
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17642096
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/642096 | NEUROLOGICAL DISEASE TREATMENT WITH COMPLEMENT INHIBITORS | Sep 10, 2020 | Pending |
Array
(
[id] => 18077366
[patent_doc_number] => 20220402978
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => POLYPEPTIDES MIMICKING EPITOPE OF BROADLY NEUTRALIZING ANTIBODY VRC01 AS ANTIGENS FOR A VACCINE PREVENTING HIV-1 INFECTION
[patent_app_type] => utility
[patent_app_number] => 17/642131
[patent_app_country] => US
[patent_app_date] => 2020-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5460
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 150
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17642131
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/642131 | POLYPEPTIDES MIMICKING EPITOPE OF BROADLY NEUTRALIZING ANTIBODY VRC01 AS ANTIGENS FOR A VACCINE PREVENTING HIV-1 INFECTION | Sep 7, 2020 | Abandoned |
Array
(
[id] => 17929790
[patent_doc_number] => 20220324915
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-13
[patent_title] => MITIGATION OF PERI-IMPLANTITIS BY DESIGN AND STABILITY OF BIFUNCTIONAL PEPTIDES WITH ANTIMICROBIAL PROPERTIES
[patent_app_type] => utility
[patent_app_number] => 17/641058
[patent_app_country] => US
[patent_app_date] => 2020-09-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14873
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17641058
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/641058 | Mitigation of peri-implantitis by design and stability of bifunctional peptides with antimicrobial properties | Sep 6, 2020 | Issued |
Array
(
[id] => 18434385
[patent_doc_number] => 20230181679
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => OPHTHALMIC COMPOSITION FOR THE TREATMENT OF UVEITIS
[patent_app_type] => utility
[patent_app_number] => 17/640679
[patent_app_country] => US
[patent_app_date] => 2020-09-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7697
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17640679
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/640679 | Ophthalmic composition for the treatment of uveitis | Sep 4, 2020 | Issued |
Array
(
[id] => 16525253
[patent_doc_number] => 20200399333
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-24
[patent_title] => HISTATINS AND METHOD OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/011273
[patent_app_country] => US
[patent_app_date] => 2020-09-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8539
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 116
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17011273
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/011273 | Histatins and method of use thereof | Sep 2, 2020 | Issued |
Array
(
[id] => 16540982
[patent_doc_number] => 20200407395
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-31
[patent_title] => CHIRAL PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 17/011264
[patent_app_country] => US
[patent_app_date] => 2020-09-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21151
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17011264
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/011264 | CHIRAL PEPTIDES | Sep 2, 2020 | Abandoned |
Array
(
[id] => 17897030
[patent_doc_number] => 20220306692
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-29
[patent_title] => PEPTIDE INHIBITORS OF FOCAL ADHESION KINASE ACTIVITY AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/638930
[patent_app_country] => US
[patent_app_date] => 2020-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23186
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -101
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17638930
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/638930 | PEPTIDE INHIBITORS OF FOCAL ADHESION KINASE ACTIVITY AND USES THEREOF | Aug 30, 2020 | Pending |
Array
(
[id] => 17895417
[patent_doc_number] => 20220305079
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-29
[patent_title] => THERAPEUTIC PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 17/634490
[patent_app_country] => US
[patent_app_date] => 2020-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31282
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -36
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17634490
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/634490 | THERAPEUTIC PEPTIDES | Aug 16, 2020 | Abandoned |
Array
(
[id] => 17897029
[patent_doc_number] => 20220306691
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-29
[patent_title] => THERAPEUTIC PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 17/634499
[patent_app_country] => US
[patent_app_date] => 2020-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31100
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -35
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17634499
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/634499 | THERAPEUTIC PEPTIDES | Aug 16, 2020 | Abandoned |
Array
(
[id] => 16451062
[patent_doc_number] => 20200360488
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-19
[patent_title] => PTH COMPOUNDS WITH LOW PEAK-TO-TROUGH RATIOS
[patent_app_type] => utility
[patent_app_number] => 16/989225
[patent_app_country] => US
[patent_app_date] => 2020-08-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33612
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -41
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16989225
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/989225 | PTH COMPOUNDS WITH LOW PEAK-TO-TROUGH RATIOS | Aug 9, 2020 | Abandoned |
Array
(
[id] => 17867076
[patent_doc_number] => 20220289811
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-15
[patent_title] => A FORMULATION OF INSULIN BASED ON CRYSTAL-SEEDING IN HYDROGELS AND METHOD THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/635401
[patent_app_country] => US
[patent_app_date] => 2020-08-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3867
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17635401
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/635401 | A FORMULATION OF INSULIN BASED ON CRYSTAL-SEEDING IN HYDROGELS AND METHOD THEREOF | Aug 6, 2020 | Pending |
Array
(
[id] => 17996725
[patent_doc_number] => 11497812
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-15
[patent_title] => Compositions and methods for inhibiting the activity of LAR family phosphatases
[patent_app_type] => utility
[patent_app_number] => 16/983879
[patent_app_country] => US
[patent_app_date] => 2020-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 15
[patent_no_of_words] => 20886
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16983879
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/983879 | Compositions and methods for inhibiting the activity of LAR family phosphatases | Aug 2, 2020 | Issued |
Array
(
[id] => 17865478
[patent_doc_number] => 20220288213
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-15
[patent_title] => INSULIN ANALOGUES WITH GLUCOSE REGULATED CONFORMATIONAL SWITCH
[patent_app_type] => utility
[patent_app_number] => 17/630258
[patent_app_country] => US
[patent_app_date] => 2020-07-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8659
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -51
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17630258
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/630258 | INSULIN ANALOGUES WITH GLUCOSE REGULATED CONFORMATIONAL SWITCH | Jul 30, 2020 | Pending |
Array
(
[id] => 18451506
[patent_doc_number] => 20230192784
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => KLF Induced Cardiomyogenesis
[patent_app_type] => utility
[patent_app_number] => 17/630263
[patent_app_country] => US
[patent_app_date] => 2020-07-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18333
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17630263
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/630263 | KLF Induced Cardiomyogenesis | Jul 29, 2020 | Pending |
Array
(
[id] => 17837746
[patent_doc_number] => 20220275051
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-01
[patent_title] => MHC CLASS II MOLECULES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/631821
[patent_app_country] => US
[patent_app_date] => 2020-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20924
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -79
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17631821
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/631821 | MHC CLASS II MOLECULES AND METHODS OF USE THEREOF | Jul 28, 2020 | Pending |
Array
(
[id] => 17775028
[patent_doc_number] => 20220241377
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-04
[patent_title] => RECEPTOR-TARGETING PEPTIDE-DRUG CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 17/629460
[patent_app_country] => US
[patent_app_date] => 2020-07-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8204
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 141
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17629460
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/629460 | RECEPTOR-TARGETING PEPTIDE-DRUG CONJUGATES | Jul 23, 2020 | Abandoned |
Array
(
[id] => 17836465
[patent_doc_number] => 20220273770
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-01
[patent_title] => GLUCOSE-RESPONSIVE INSULIN CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 17/629501
[patent_app_country] => US
[patent_app_date] => 2020-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33975
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17629501
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/629501 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | Jul 22, 2020 | Abandoned |
Array
(
[id] => 17836455
[patent_doc_number] => 20220273760
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-01
[patent_title] => A TEIXOBACTIN ANALOGUE AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/624830
[patent_app_country] => US
[patent_app_date] => 2020-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26721
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17624830
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/624830 | Teixobactin analogue and use thereof | Jul 22, 2020 | Issued |
Array
(
[id] => 18535905
[patent_doc_number] => 20230240991
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => PROTEOPHOSPHOLIPOSOMES HAVING HDL-TYPE VESICLES
[patent_app_type] => utility
[patent_app_number] => 17/300210
[patent_app_country] => US
[patent_app_date] => 2020-07-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19577
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17300210
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/300210 | PROTEOPHOSPHOLIPOSOMES HAVING HDL-TYPE VESICLES | Jul 21, 2020 | Pending |